142 related articles for article (PubMed ID: 36163560)
81. De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report.
Ding Y; Dong H; Li Y; Liu L; Cai Y; Wang Y; Tian S; Dai C
Medicine (Baltimore); 2022 Jul; 101(29):e29332. PubMed ID: 35866776
[TBL] [Abstract][Full Text] [Related]
82. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
83. Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.
Singh V; Guleria P; Malik PS; Mohan A; Thulkar S; Pandey RM; Luthra K; Arava S; Ray R; Jain D
Curr Probl Cancer; 2019 Oct; 43(5):391-401. PubMed ID: 30591192
[TBL] [Abstract][Full Text] [Related]
84. Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
Tanizaki J; Banno E; Togashi Y; Hayashi H; Sakai K; Takeda M; Kaneda H; Nishio K; Nakagawa K
Lung Cancer; 2016 Nov; 101():11-15. PubMed ID: 27794398
[TBL] [Abstract][Full Text] [Related]
85. Discrepancy of epidermal growth factor receptor mutation in lung adenocarcinoma presenting as multiple ground-glass opacities.
Liu M; He WX; Song N; Yang Y; Zhang P; Jiang GN
Eur J Cardiothorac Surg; 2016 Nov; 50(5):909-913. PubMed ID: 27032467
[TBL] [Abstract][Full Text] [Related]
86. Major challenges in accurate mutation detection of multifocal lung adenocarcinoma by next-generation sequencing.
Qiu T; Li W; Zhang F; Wang B; Ying J
Cancer Biol Ther; 2020; 21(2):170-177. PubMed ID: 31651223
[No Abstract] [Full Text] [Related]
87. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
[TBL] [Abstract][Full Text] [Related]
88. Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis.
Mehta A; Vasudevan S
Cancer Treat Res Commun; 2021; 28():100398. PubMed ID: 34052672
[TBL] [Abstract][Full Text] [Related]
89. Screening for germline EGFR T790M mutations through lung cancer genotyping.
Oxnard GR; Miller VA; Robson ME; Azzoli CG; Pao W; Ladanyi M; Arcila ME
J Thorac Oncol; 2012 Jun; 7(6):1049-52. PubMed ID: 22588155
[TBL] [Abstract][Full Text] [Related]
90. Genotype-phenotype correlation in Chinese patients with pulmonary mixed type adenocarcinoma: Relationship between histologic subtypes, TITF-1/SP-A expressions and EGFR mutations.
Jie-Liu ; Li XY; Zhao YQ; Liu RQ; Zhang JB; Ma J; Chen LJ; Hu XF
Pathol Res Pract; 2014 Mar; 210(3):176-81. PubMed ID: 24370340
[TBL] [Abstract][Full Text] [Related]
91. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.
Yang Z; Yang N; Ou Q; Xiang Y; Jiang T; Wu X; Bao H; Tong X; Wang X; Shao YW; Liu Y; Wang Y; Zhou C
Clin Cancer Res; 2018 Jul; 24(13):3097-3107. PubMed ID: 29506987
[No Abstract] [Full Text] [Related]
92. Minute Pulmonary Meningothelial-like Nodules Showing Multiple Ring-shaped Opacities.
Harada M; Aono Y; Yasui H; Uto T; Sato J; Imokawa S; Suzuki S; Tanioka F; Suda T
Intern Med; 2019 Nov; 58(21):3149-3152. PubMed ID: 31327818
[TBL] [Abstract][Full Text] [Related]
93. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
94. [Advanced Pneumonic-type Lung Carcinoma: A Retrospective Study of Clinical-radiological-pathological Characteristics with Survival Analysis in A Single Chinese Hospital].
Liu Y; Li J; Wang S; Chen M; Zhao J; Jiang D; Zhong W; Xu Y; Wang M
Zhongguo Fei Ai Za Zhi; 2019 Jun; 22(6):329-335. PubMed ID: 31196365
[TBL] [Abstract][Full Text] [Related]
95. Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Chen M; Xu Y; Zhao J; Zhong W; Zhang L; Bi Y; Wang M
EBioMedicine; 2019 Apr; 42():304-310. PubMed ID: 30878600
[TBL] [Abstract][Full Text] [Related]
96. Ground glass opacities: Imaging, pathology, and gene mutations.
Sun F; Xi J; Zhan C; Yang X; Wang L; Shi Y; Jiang W; Wang Q
J Thorac Cardiovasc Surg; 2018 Aug; 156(2):808-813. PubMed ID: 29753514
[TBL] [Abstract][Full Text] [Related]
97. Two lung adenocarcinomas in the same lobe: multiple primaries or intrapulmonary metastasis?
Yoshimoto K; Yoshida J; Ishii G; Nishimura M; Hishida T; Nagai K
Ann Thorac Cardiovasc Surg; 2011; 17(6):584-7. PubMed ID: 21881358
[TBL] [Abstract][Full Text] [Related]
98. Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection.
Kim H; Chae KJ; Yoon SH; Kim M; Keam B; Kim TM; Kim DW; Goo JM; Park CM
Eur Radiol; 2018 Feb; 28(2):861-868. PubMed ID: 28786010
[TBL] [Abstract][Full Text] [Related]
99. Lung adenocarcinoma in a patient with a cis EGFR L858R-K860I doublet mutation identified using NGS-based profiling test: Negative diagnosis on initial companion test and successful treatment with osimertinib.
Onozawa H; Saito H; Sunami K; Kubo T; Yamamoto N; Kasajima R; Ohtsu T; Hiroshima Y; Kanamori H; Yokose T; Miyagi Y
Thorac Cancer; 2020 Dec; 11(12):3599-3604. PubMed ID: 33034420
[TBL] [Abstract][Full Text] [Related]
100. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
